Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Markets to 2022 - How Will Immunotherapies Such as Keytruda Contribute to the 8.7% Growth? - Research and Markets

DUBLIN, June 2, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" report to their offering.

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 - a high-risk age range for lung cancer.

As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Xalkori and Gilotrif. Opdivo (nivolumab) - a mAb immune checkpoint inhibitor targeted towards Programmed cell Death (PD) 1 - is a recent market entrant, gaining approval for treating advanced or metastatic squamous NSCLC patients in Japan in 2015 and in Australia in 2016.

While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Therapies that target mutant T790M and KRAS are being developed in the pipeline, with osimertinib, targeting T790M, gaining approval in Japan in 2016.

Scope

The NSCLC Asia-Pacific market will be valued at $4.9 billion in 2022, growing from $2.7 billion in 2015 at a CAGR of 8.7%. - How will immunotherapies such as Keytruda contribute to the growth? - What effect will patent expirations of currently branded therapies have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.

- What are the common targets and mechanisms of action of pipeline therapies?

- Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?

- What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

- How have the late-stage therapies performed in clinical trials?

- How would the approval of rociletinib to treat T790M mutant patients affect the competitive landscape, with its competitor osimertinib (AZD-9291) already approved in Japan in 2016?

- How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

- How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?

- How could changes in risk factors such as population age, smoking habits and pollution influence the market?

Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.

- How do deal frequency and value compare between target families and molecule types?

- What were the terms and conditions of key licensing deals?

Companies Mentioned

- AbbVie

- AstraZeneca

- Boehringer Ingelheim

- Bristol-Myers Squibb

- Celgene

- Clovis

- Eli Lilly

- Merck

- Novartis

- OncoGenex

- Pfizer

- Recombio

- Roche

- Transgene

For more information visit http://www.researchandmarkets.com/research/mv3rdf/nonsmall_cell

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets